In this two-part series you’ll learn about technologies to reveal both the molecular and physiologically relevant mechanisms of cancer from DNA to receptors and cell avidity-based “living drug” candidate selection. Featured are single molecule force measurements by optical trapping with simultaneous integrated imaging modes (part 1) and functional profiling of CAR-T, CAR-NK, and TCRtg using cell avidity measurements (part 2).
Part 1 | Title to be announced | March 21 at 10 a.m.
Part 2 | Cellular avidity as an emerging biomarker for candidate selection of cell-based immunotherapies | March 28 at 10 a.m.
